Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 69.9% | +31.3% |
| JACKSON III, WALTER | 1 | 100.0% | +0.0% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251030 | Modified Red Blood Cells and Uses Thereof for Delivering Agents | JACKSON III, WALTER | 9d |
| 18264098 | Modified Red Blood Cells and Uses Thereof For Treating Hyperuricemia and Gout | LANKFORD JR, LEON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264098 | Modified Red Blood Cells and Uses Thereof For Treating Hyperuricemia and Gout | LANKFORD JR, LEON B | — |
| 17906435 | Modified Red Blood Cells and Uses Thereof for Delivering Agents | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1638 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264098 | Modified Red Blood Cells and Uses Thereof For Treating Hyperuricemia and Gout | LANKFORD JR, LEON B | 1657 | §102§103 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18251030 | Modified Red Blood Cells and Uses Thereof for Delivering Agents | JACKSON III, WALTER | 1638 | §103§112Other | Non-Final OA | 9d | Pending | Apr 28, 2023 |
| 17906435 | Modified Red Blood Cells and Uses Thereof for Delivering Agents | STEADMAN, DAVID J | 1656 | DP | Non-Final OA | — | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial